Last reviewed · How we verify

CILO

Gilead Sciences · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

CILO is a Small molecule drug developed by Gilead Sciences. It is currently FDA-approved. Also known as: GS-9674.

Cilofexor (CILO) is being studied in clinical trials for the treatment of Nonalcoholic Steatohepatitis, Primary Sclerosing Cholangitis, Compensated Cirrhosis, and Myocardial Infarction, among other conditions. Cilofexor is being investigated in combination with Semaglutide (SEMA) and Firsocostat (FIR) in a clinical trial.

At a glance

Generic nameCILO
Also known asGS-9674
SponsorGilead Sciences
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CILO

What is CILO?

CILO is a Small molecule drug developed by Gilead Sciences.

Who makes CILO?

CILO is developed and marketed by Gilead Sciences (see full Gilead Sciences pipeline at /company/gilead).

Is CILO also known as anything else?

CILO is also known as GS-9674.

What development phase is CILO in?

CILO is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing